Rosetta Genomics Debt 2025

Rosetta Genomics Aktienanalyse

What does Rosetta Genomics do?

Rosetta Genomics Ltd is a company specializing in personalized medicine, focused on the development and commercialization of diagnostic tests based on RNA interference and NGS technologies for cancer diseases. The company was founded in 2000 and has its headquarters in Israel, with offices in the USA and Europe. The history of Rosetta Genomics began with the development of MicroRNA (miRNA), RNA molecules that act as regulators of gene expression in cells. The company developed a technology that allows for the identification of specific miRNAs that are characteristic of different types of cancers. As a result, Rosetta Genomics started developing a series of diagnostic tests based on these miRNAs to enable personalized therapy for cancer patients. Rosetta Genomics' business model is based on the commercialization of diagnostic tests for various cancer types. These tests can be requested by doctors and other medical professionals to determine the best treatment for patients. The company works closely with clinicians and researchers to continually improve its tests and stay up to date with the latest technology. The company operates in two main divisions: RosettaGX and RosettaWGX. RosettaGX offers diagnostic tests for various cancer types, including lung cancer, thyroid cancer, and colorectal cancer. These tests utilize Rosetta Genomics' proprietary RNA interference technology to identify specific miRNAs indicative of a particular type of cancer. On the other hand, RosettaWGX offers NGS services that allow researchers and pharmaceutical companies to collect and analyze DNA sequencing data to gain insights into the genetics of cancer. Some of the products offered by Rosetta Genomics include the miRview® Lung Test, miRview® mets2 Test, and miRview® Thyroid Test. The miRview® Lung Test identifies specific miRNAs characteristic of various types of lung tumors to enable an accurate diagnosis. The miRview® mets2 Test can determine the origin of cancer cells that have spread from the primary site, enabling targeted treatment. The miRview® Thyroid Test enables an accurate diagnosis of thyroid cancer and can determine the likelihood of a more aggressive form of the disease. Overall, Rosetta Genomics has developed a wide range of diagnostic tests and services based on a unique technology platform to enable personalized medicine for cancer patients. The company collaborates closely with doctors, researchers, and pharmaceutical companies to continually improve its tests and stay at the forefront of technology. With its innovative products and services, Rosetta Genomics is an important player in the field of personalized medicine and contributes to improving treatment outcomes for cancer patients. Rosetta Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Rosetta Genomics's Debt Structure

Rosetta Genomics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Rosetta Genomics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Rosetta Genomics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Rosetta Genomics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Rosetta Genomics stock

What is the debt of Rosetta Genomics this year?

Rosetta Genomics has a debt level of 0 USD this year.

What was the debt of Rosetta Genomics compared to the previous year?

The debt of Rosetta Genomics has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Rosetta Genomics?

High debt can pose a risk for investors of Rosetta Genomics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Rosetta Genomics?

Low debt means that Rosetta Genomics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Rosetta Genomics affect the company?

An increase in debt of Rosetta Genomics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Rosetta Genomics affect the company?

A reduction in debt of Rosetta Genomics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Rosetta Genomics?

Some factors that can influence the debt of Rosetta Genomics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Rosetta Genomics so important for investors?

The debts of Rosetta Genomics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Rosetta Genomics take to change the debt?

To change the debt, Rosetta Genomics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Rosetta Genomics pay?

Over the past 12 months, Rosetta Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rosetta Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rosetta Genomics?

The current dividend yield of Rosetta Genomics is .

When does Rosetta Genomics pay dividends?

Rosetta Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rosetta Genomics?

Rosetta Genomics paid dividends every year for the past 0 years.

What is the dividend of Rosetta Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rosetta Genomics located?

Rosetta Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rosetta Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rosetta Genomics from 1/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/27/2025.

When did Rosetta Genomics pay the last dividend?

The last dividend was paid out on 1/27/2025.

What was the dividend of Rosetta Genomics in the year 2024?

In the year 2024, Rosetta Genomics distributed 0 USD as dividends.

In which currency does Rosetta Genomics pay out the dividend?

The dividends of Rosetta Genomics are distributed in USD.